Diabetes and COVID-19
Diabetes and COVID-19
Buch
- Considerations and Clinical Management
- Herausgeber: Alyson K. Myers
lieferbar innerhalb 2-3 Wochen
(soweit verfügbar beim Lieferanten)
(soweit verfügbar beim Lieferanten)
EUR 106,66*
Verlängerter Rückgabezeitraum bis 31. Januar 2025
Alle zur Rückgabe berechtigten Produkte, die zwischen dem 1. bis 31. Dezember 2024 gekauft wurden, können bis zum 31. Januar 2025 zurückgegeben werden.
- Springer International Publishing, 06/2024
- Einband: Kartoniert / Broschiert, Paperback
- Sprache: Englisch
- ISBN-13: 9783031285387
- Bestellnummer: 11895241
- Umfang: 240 Seiten
- Auflage: 2023
- Gewicht: 414 g
- Maße: 235 x 155 mm
- Stärke: 13 mm
- Erscheinungstermin: 12.6.2024
- Serie: Contemporary Endocrinology
Achtung: Artikel ist nicht in deutscher Sprache!
Weitere Ausgaben von Diabetes and COVID-19
Klappentext
Managing COVID-19 alone can be a difficult in many cases, but for persons with pre-existing conditions such as diabetes the challenge can be all the greater, and specific considerations need to be taken when prescribing treatment to manage them. This book is a culmination of scientific work driven by personal conviction to enhance the care provided to the vulnerable populations COVID-19 patients with diabetes. It spans topics from the epidemiology and predictors of complications and increased mortality in COVID-19, to in-depth discussion of the pathophysiology of the disease. Pathophysiology of COVID-19 is addressed comprehensively as common soil pathogenetic pathways, and by organ system such as the lung, the kidney and most pertinently for diabetes, the diabetic foot ulcers and diabetes co-morbidities. A multi-disciplinary approach was needed to manage these complex patients; thus, the authors represent a variety of disciplines including pharmacology, endocrinology, nephrology, infectious diseases, podiatry, vascular surgery, pulmonary / critical care, and general medicine.Written by experts in the field, Diabetes and COVID-19: Considerations and Clinical Management is a blueprint for treatment of patients with both conditions.
Diabetes and COVID-19
EUR 106,66*